genOway Société anonyme Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
genOway Société anonyme has been growing earnings at an average annual rate of 69.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 14% per year. genOway Société anonyme's return on equity is 7.1%, and it has net margins of 4.5%.
Anahtar bilgiler
69.1%
Kazanç büyüme oranı
n/a
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 30.8% |
| Gelir büyüme oranı | 14.0% |
| Özkaynak getirisi | 7.1% |
| Net Marj | 4.5% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
These 4 Measures Indicate That genOway Société anonyme (EPA:ALGEN) Is Using Debt Reasonably Well
Jun 08
genOway Société anonyme's (EPA:ALGEN) Price Is Right But Growth Is Lacking
Jan 20We Think genOway Société anonyme (EPA:ALGEN) Can Stay On Top Of Its Debt
Sep 27We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
May 31We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
Nov 01Gelir ve Gider Dağılımı
genOway Société anonyme nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 28 | 1 | 10 | 0 |
| 31 Mar 24 | 27 | 1 | 9 | 0 |
| 31 Dec 23 | 27 | 2 | 9 | 0 |
| 30 Sep 23 | 24 | 2 | 7 | 0 |
| 30 Jun 23 | 23 | 2 | 9 | 0 |
| 31 Mar 23 | 22 | 1 | 8 | 0 |
| 31 Dec 22 | 21 | 1 | 8 | 0 |
| 30 Sep 22 | 21 | 1 | 8 | 0 |
| 30 Jun 22 | 21 | 1 | 8 | 0 |
| 31 Mar 22 | 20 | 0 | 8 | 0 |
| 31 Dec 21 | 20 | 0 | 8 | 0 |
| 30 Sep 21 | 20 | 0 | 10 | 0 |
| 30 Jun 21 | 18 | 0 | 8 | 0 |
| 31 Mar 21 | 17 | -1 | 8 | 0 |
| 31 Dec 20 | 16 | -1 | 7 | 0 |
| 30 Sep 20 | 16 | -1 | 7 | 0 |
| 30 Jun 20 | 15 | -1 | 7 | 0 |
| 31 Mar 20 | 14 | -1 | 7 | 0 |
| 31 Dec 19 | 14 | -1 | 7 | 0 |
| 30 Sep 19 | 14 | -1 | 7 | 0 |
| 30 Jun 19 | 15 | -1 | 7 | 0 |
| 31 Mar 19 | 15 | 0 | 7 | 0 |
| 31 Dec 18 | 15 | 1 | 6 | 0 |
| 30 Sep 18 | 14 | 1 | 6 | 0 |
| 30 Jun 18 | 13 | 1 | 5 | 0 |
| 31 Mar 18 | 13 | 1 | 5 | 0 |
| 31 Dec 17 | 13 | 2 | 5 | 0 |
| 30 Sep 17 | 13 | 2 | 5 | 0 |
| 30 Jun 17 | 13 | 2 | 5 | 0 |
| 31 Mar 17 | 12 | 1 | 5 | 0 |
| 31 Dec 16 | 12 | 1 | 5 | 0 |
| 30 Sep 16 | 11 | 0 | 5 | 0 |
| 30 Jun 16 | 10 | 0 | 4 | 0 |
| 31 Mar 16 | 10 | 0 | 4 | 0 |
| 31 Dec 15 | 10 | 0 | 4 | 0 |
| 30 Sep 15 | 10 | 0 | 4 | 0 |
| 30 Jun 15 | 10 | 0 | 4 | 0 |
| 31 Mar 15 | 10 | 0 | 4 | 0 |
| 31 Dec 14 | 10 | 0 | 4 | 0 |
| 30 Sep 14 | 10 | 0 | 4 | 0 |
| 30 Jun 14 | 10 | 0 | 4 | 0 |
| 31 Mar 14 | 10 | 0 | 4 | 0 |
| 31 Dec 13 | 10 | 0 | 4 | 0 |
Kaliteli Kazançlar: ALGEN has high quality earnings.
Büyüyen Kar Marjı: ALGEN's current net profit margins (4.5%) are lower than last year (7%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ALGEN has become profitable over the past 5 years, growing earnings by 69.1% per year.
Büyüme Hızlandırma: ALGEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: ALGEN had negative earnings growth (-21.2%) over the past year, making it difficult to compare to the Biotechs industry average (-20.8%).
Özkaynak Getirisi
Yüksek ROE: ALGEN's Return on Equity (7.1%) is considered low.